Develops and commercializes blood-based biomarker tests and predictive analytics products and services for pregnant women, their physicians, and health care payers.
10-K for FY2025, filed Mar 18, 2026
Sera earns revenue from PreTRM tests, seeking payment through health systems, physician networks and insurers; it counts a test sale when results are delivered.
10-K for FY2025, filed Mar 18, 2026
$81K
10-K for FY2025, filed Mar 18, 2026
$81K ↗
Sera targets health care providers, insurers and consumers for PreTRM, seeking reimbursement through integrated systems, physician networks and major insurers. Its filing also describes direct patient or consumer payment as a possible model for other products or market segments.
10-K for FY2025, filed Mar 18, 2026
No. It lost $31.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$8.1MView ↗
8-K, filed Aug 19, 2026
On August 14, 2026, the Board of Directors appointed Scott Gleason to serve as the next Chief Financial Officer and Treasurer of Sera…View ↗
Flat. Revenue was $81K in FY2025, about the same as the $82K of FY2021.
Broader product scope
The older report centered on discovering and commercializing biomarker tests; the latest report also includes predictive analytic products and services in its business description.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 18, 2026We are a women’s health company utilizing our proprietary proteomics and bioinformatics platform to discover, develop, and commercialize…View ↗
We are a women’s health company utilizing our proprietary proteomics and bioinformatics platform, and significant data resources to improve…View ↗
Loading...